WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles
WHO TRS 986, Annex 2 is the World Health Organization's main-principles Good Manufacturing Practices text for pharmaceutical products, published as Annex 2 of the 48th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in Technical Report Series No. 986 (2014). It is the reference GMP standard underpinning the WHO Certification Scheme for products in international commerce and the WHO Prequalification programme. It covers the pharmaceutical quality system, personnel, premises and equipment, documentation, production, quality control, contract manufacture and analysis, complaints, recalls, and self-inspection, and is widely adopted by national regulators without their own detailed GMP.
What this does not cover
stated in the document's own scope- It does not give the detailed requirements for sterile products, which are in a separate WHO GMP annex (TRS 1044, Annex 2).
- It does not cover active pharmaceutical ingredients in depth; WHO addresses APIs in a dedicated GMP text aligned with ICH Q7.
- It does not cover distribution, which WHO addresses through its Good Distribution Practices guidance (TRS 957, Annex 5).
- It does not set product specifications or analytical acceptance criteria; those come from the pharmacopoeias and product-specific standards.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
WHO TRS 986, Annex 2 is the World Health Organization's baseline set of GMP principles for pharmaceutical products. It exists to give countries and manufacturers a single, internationally recognised GMP reference, particularly where a national authority has not published its own detailed code. The text lays out the elements of a compliant manufacturing operation — a functioning quality system, competent people, suitable premises and equipment, thorough documentation, controlled production and quality control, and the oversight systems of complaints, recalls, and self-inspection. It is the GMP foundation for the WHO Certification Scheme and the WHO Prequalification of Medicines programme.
Legal basis & how it acquires force
WHO TRS 986, Annex 2 is a recommendation, not a treaty or a directly binding law. It acquires force in two ways: national regulators adopt it, wholly or with modification, as their own GMP requirement, and it is the reference standard for the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce and for WHO Prequalification. Where a country has no detailed GMP of its own, adoption of the WHO text is what makes it enforceable domestically; where WHO Prequalification is required, compliance is a market condition.
Document structure
| Part | Covers |
|---|---|
| Quality management and quality risk management | The pharmaceutical quality system, principles of GMP, quality control, product quality review, and risk management. |
| Personnel, hygiene, and premises | Organisation and responsibilities, training, sanitation and hygiene, and the design and maintenance of premises. |
| Equipment, materials, and documentation | Qualification of equipment, control of starting and packaging materials, and the documentation system and records. |
| Production and quality control | Good practices in production, prevention of cross-contamination, and good practices in quality control including sampling and testing. |
| Outsourcing and oversight systems | Contract production and analysis, complaints, product recalls, and self-inspection and quality audits. |
Key requirements
- Operate a pharmaceutical quality system that incorporates GMP and quality risk management, with senior-management responsibility for quality.
- Maintain qualified personnel with defined responsibilities, training, and hygiene appropriate to the operations performed.
- Design and maintain premises and equipment to prevent contamination, mix-ups, and errors, and qualify them for their intended use.
- Document all activities through master formulae, procedures, records, and specifications so the history of every batch can be reconstructed.
- Control production and in-process activities against validated processes, and release product only after independent quality-control testing.
- Govern contract manufacture and analysis through a written agreement that defines each party's GMP responsibilities.
- Operate complaints, recall, self-inspection, and quality-management-review systems to detect and correct quality problems.
Implementation tips
- Read Annex 2 together with the WHO validation and sterile-products annexes, since the main-principles text points to them for detailed process requirements.
- Map the Annex 2 chapters onto your existing quality-system procedures to show a supply destination that WHO GMP is fully covered.
- Keep qualification and validation evidence current, since the WHO Certification Scheme and Prequalification rely on it as the basis for the GMP statement.
- Where a market accepts either WHO or ICH-region GMP, document how a single quality system satisfies both.
International alignment
WHO GMP main principles are broadly consistent with the GMP frameworks of PIC/S (PE 009) and the EU (EudraLex Volume 4), and with ICH Q7 for active pharmaceutical ingredients, Q9 for risk management, and Q10 for the pharmaceutical quality system, though the texts differ in detail and legal status. WHO GMP is the reference for the Certification Scheme and Prequalification, and many national authorities in emerging markets adopt it directly. Annex 2 sits alongside separate WHO annexes for sterile products, excipients, and radiopharmaceuticals.
WHO TRS 986, Annex 2: frequently asked questions
Quick answers to common questions about WHO TRS 986, Annex 2.
What is WHO TRS 986, Annex 2?
It is the World Health Organization's main-principles Good Manufacturing Practices for pharmaceutical products, published in 2014 as Annex 2 of the 48th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.
Where is WHO GMP legally required?
It is not automatically binding anywhere; it becomes enforceable where a national authority adopts it as its GMP standard, and it is a condition of the WHO Certification Scheme and WHO Prequalification of Medicines.
How does WHO GMP relate to PIC/S and EU GMP?
The three are broadly aligned in their principles, and PIC/S and WHO cooperate closely, but they are separate texts with different detail and legal standing. A manufacturer often builds one quality system that satisfies all three.
Does Annex 2 cover sterile manufacturing?
Only in general terms. Detailed sterile-product requirements are in a separate WHO GMP annex, published as TRS 1044, Annex 2, which Annex 2 references for that scope.